Morning Call, May 23
Health Care: Drugs
Tekmira Pharmaceuticals Corporation (TKMR: NASDAQ)
$4.70 -0.03 | -0.63%
05/23/13 - 11:12 AM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 29.95M | -9.73M | -12.41M | -9.33M |
| Operating Gains/Losses | 0.00 | 58.67K | 7.18K | 356.92K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 133.15K | 2.46M | -2.39M | -282.81K |
| (Increase) Decrease in Inventories | 0.00 | 147.63K | -150.71K | 166.67K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -197.28K | -2.13M | 498.02K | 1.13M |
| (Decrease) Increase In Other Current Liabilities | -2.19M | 619.11K | 2.16M | 671.70K |
| (Increase) Decrease In Other Working Capital | -294.65K | 127.16K | -557.17K | 0.00 |
| Other Non-Cash Items | 4.90M | 86.54K | 650.52K | 253.73K |
| Net Cash From Continuing Operations | 33.27M | -7.52M | -11.25M | -5.24M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 33.27M | -7.52M | -11.25M | -5.24M |
| Sale of Property, Plant & Equipment | 2.50K | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 5.47M |
| Purchases of Property, Plant & Equipment | -14.90K | -58.45K | -830.82K | -1.62M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -12.40K | -58.45K | -830.82K | 3.85M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 3.93M | 4.46M | 34.91K | 7.53K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 635.16K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 4.57M | 4.46M | 34.91K | 7.53K |
| Effect of Exchange Rate Changes | -29.42K | 19.68K | -7.18K | -356.92K |
| Net Change in Cash & Cash Equivalents | 37.80M | -3.10M | -12.05M | -1.74M |
Portfolios with TKMR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest TKMR Headlines from TheStreet
- Tekmira's Collaborators At The National Cancer Institute Present Preclinical Data At The Annual Meeting Of The American Association For Cancer Research (AACR) 04.10.13 | 08:04 am
- Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial At American Association For Cancer Research (AACR) Meeting 04.09.13 | 03:04 pm
- Tekmira Provides Corporate Update And Announces Year-End Audited 2012 Results 03.27.13 | 04:03 pm
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
- Tekmira Conference Call And Webcast Advisory: Corporate Update And Year-End 2012 Financial Results 03.20.13 | 04:03 pm
- Tekmira Outlines Key 2013 Product Development And Corporate Milestones 02.12.13 | 08:02 am
- Tekmira To Webcast Presentation At 15th Annual BIO CEO & Investor Conference 02.06.13 | 08:02 am
- Tekmira To Present TKM-PLK1 Phase 1 Clinical Trial Results At AACR 02.04.13 | 08:02 am
- Tekmira's LNP Technology Highlighted In Peer-Reviewed Publication, Cancer Discovery 01.31.13 | 04:01 pm
- 3 Pharma Stocks Leaping on Unusual Volume 01.10.13 | 02:01 pm
Press Releases for TKMR
Partner Headlines for TKMR
- Tekmira Says Expects to Receive Notice by Sept 30 on DoD's Decision Related to Order on TKM-EBOLA Program - Benzinga 08.31.12 | 04:08 pm
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Tekmira Provides Periodic Update to Litigation; Alnylam Pharma Files Suit Against Tekmira - Benzinga 01.17.12 | 04:01 pm
- Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia - Benzinga 01.10.12 | 04:01 pm
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- Tekmira and Collaborators Present Data at the AACRMeeting on Tekmira's Lead Oncology Product, TKM-PLK1, and an Oncology Product Candidate Targeting Kinase WEE1 - Benzinga 04.04.11 | 04:04 pm
- Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information - Benzinga 03.16.11 | 04:03 pm
